A Phase Ib/II, multicenter, open-label, two-part study to evaluate the efficacy, safety, pharmacokinetics, and recommended dose of the combination of BNT324 and BNT327 in participants with advanced lung cancer.
Principal Investigator
Dott.ssa Chiara Lazzari
Contact Information for Access
Phase
FASE II
Status
ATTIVO
Objective of the study
The primary objective is to evaluate the efficacy and determine the recommended dose of the BNT324 + BNT327 combination in patients with advanced lung cancer.
Pathologies
Lung Cancer
Medication
BNT324 (antibody conjugate targeting B7-H3)
BNT327 - Pumitamig (bispecific antibody for PD-L1 and VEGF-A)
Who is eligible to participate in the study?
Patients aged 18 years or older who meet the study’s eligibility criteria—whether treatment-naive or previously treated—and who have a diagnosis of microcytoma SCLC or NSCLC of any histology, with any PD-L1 expression level, and with the presence of mutations, may participate in this study.
View the full study Back to search page